Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and inspiring, because that oh-so-familiar routine of meetings, deadlines, conference calls, and whatever else has, of course, returned. So what else can we do but turn to a few cups of stimulation to cope? Our choice today is butter pecan, for those seeking ideas. Speaking of ideas, here is the latest menu of tidbits to help you on your journey today. We hope all goes well and, as always, encourage you to keep in touch. We enjoy the tips, feedback and suggestions …

Allergan (AGN) disclosed that two influential advisory firms — Institutional Shareholder Services and Glass Lewis — urged its shareholders to vote against a proposal by the Appaloosa hedge fund to immediately separate the chief executive officer and chairman roles. Appaloosa, led by billionaire David Tepper, has been pressing Allergan since last year to separate the two roles. Instead, the drug maker recently committed to separating the jobs during its next leadership transition. ISS noted Allergan added six independent directors since 2016.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy